Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, and ImaginAb, a market leading global provider in immune-oncology imaging agents, shared initial results of a study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis.
June 30, 2021
· 4 min read
